Stock CTNM CONTINEUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Contineum Therapeutics, Inc.

Equities

CTNM

US21217B1008

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
15.32 USD +2.13% Intraday chart for Contineum Therapeutics, Inc. -2.79% -.--%
May. 20 Contineum Therapeutics, Inc. Appoints Troy Ignelzi as Independent Member of Its Board of Directors and as Chair of the Audit Committee CI
Apr. 30 Morgan Stanley Starts Contineum Therapeutics With Overweight Rating MT

Evolution of the average Target Price on Contineum Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5.AN9JxAne07-41IN2q30fOERqoSEcej-HIbKr4WFUGpo.U5YliVPspvXdt9Q700xsb30F0k5vOV3RdIXxuygcU9lxhiecQou608ma9A~d56236cf2468c9169b0c41b26ef38281

Analyst Recommendations on Contineum Therapeutics, Inc.

Morgan Stanley Starts Contineum Therapeutics With Overweight Rating MT
Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target MT
RBC Initiates Contineum Therapeutics at Outperform, Speculative Risk With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
15.32 USD
Average target price
28 USD
Spread / Average Target
+82.77%
High Price Target
30 USD
Spread / Highest target
+95.82%
Low Price Target
25 USD
Spread / Lowest Target
+63.19%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Contineum Therapeutics, Inc.

RBC Capital Markets
Stifel Nicolaus
Morgan Stanley

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CTNM Stock
  4. Consensus Contineum Therapeutics, Inc.